fibrate

DRUG2 trials

Sponsors

University of Campania Luigi Vanvitelli, Academisch Medisch Centrum

Conditions

Diabetic NephropathyFamilial Dysbetalipoproteinemia Fredrickson Type III hyperlipoproteinemia

Phase 4

Nephropathy In Type 2 Diabetes and Cardio-renal Events

CompletedNCT00535925

University of Campania Luigi VanvitelliDiabetic Nephropathy

Start: 2005-10-31End: 2019-05-31Updated: 2020-08-03

A randomized, double blind, cross-over trial to study the effects of adding bezafibrate to standard lipid lowering therapy on postprandial lipids in patients with Familial Dysbetalipoproteinemia

Active, not recruitingNL-OMON43954

Academisch Medisch CentrumFamilial Dysbetalipoproteinemia Fredrickson Type III hyperlipoproteinemia

Start: 2015-11-04Target: 15Updated: 2024-02-28

Related Papers

The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial.

2022-11-0761 citations

Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease

Cardiovascular Diabetology2021-07-16126 citations

Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8 years follow up study.

2016-10-1311 citations